Year: 2022

NETWORKING WITH ACCOMPLISHED PEOPLE can be easy if you ask them for only 20 minutes of their time as an expert in your desired field by phone. Do not ask for a job, just career advice. Do your homework and be prepared. At the end, ask if they can introduce you to somebody else senior in the field to continue your data quest. In my experience, people rarely say no, provided you follow this advice. If you follow up and keep in periodic touch, you will form lasting and important networks. http://lnkd.in/ThUwK7 View in LinkedIn

EUROPE IS STILL A KNOWLEDGE SUPERPOWER, as these awards show, and their intent is to close the gap with the US. These two very significant awards are bound to generate numerous collaborations, IP, and Tech spinouts. A very innovative and bold step in the right direction of supporting Tech research. http://lnkd.in/paX4Fs View in LinkedIn

STAR TRECK ARRIVES in our offices with the many occasions of news like this. The most important entrepreneurial question is to stand on the shoulders of giants and ask: "what else can this be applied to?" http://lnkd.in/FDAkP6 View in LinkedIn

BIOLOGICAL DRUGS ARE BECOMING HALF OF DRUG APPROVALS and the face of future medicine. These enormous numbers illustrate the value generation from a single big hit in pharmaceuticals. http://lnkd.in/QVRs6k View in LinkedIn

GOOD BOARDS ARE KEY FOR GOOD COMPANIES. This excellent article summarizes key elements on both sides of the table. Memorable reading, and a MUST READ for all young companies thinking a out a board for the first time. http://lnkd.in/iE5EqQ View in LinkedIn

AUTOLOGOUS NERVE CELL IMPLANTS FOR PARALYSIS have been a long time coming, but here is the first approved trial. Knowledge of making mature cells regrow has advanced considerably in recent decades. This is a different type of stem cell treatment, all using the body's own cells to repair a lesion. http://lnkd.in/ZKdKQ4 View in LinkedIn

ROBOTS APPROVED IN HOSPITALS, a first of breed. Watch this space for remote sensing and more telemedicine advances. Already new remote sensing technology is being developed to help monitor elders at home. http://lnkd.in/SXNG2a View in LinkedIn

CUSTOMER SURVEYS can be a Go/NoGo decision for your emerging business plan. As this article describes, it is important to do your homework to see if your intended customer would actually use your product. VCs will gain comfort from well-constructed quantitative data from such surveys, which should be short and sweet, or your response rate will be poor. http://lnkd.in/Gpm-zX View in LinkedIn

BIOPHARMA ENTREPRENEURS MUST NOT FALL IN LOVE WITH THEIR INVENTION, but rather set up a series of Go/NoGo decision points. I have seen too many scientific founders devote themselves blindly to their molecule, become blind to the adverse data, and in rare instances actually hide or lie about the adverse data (I have seen this three times in 25 years). View in LinkedIn

OVER-SHOPPING A DEAL CAN KILL IT. When investors smell that a company has been round the circuit twice, their suspicions are raised. Rather than be praised for leaving no stone unturned, the CEO is rejected because nobody wants a reject. Keeping your kimono closed, and being highly selective who you show your plan to, will attract more attention. Investors hate to be locked out of an over-subscribed financing, and this is the most desirable (and hardest to achieve) outcome for a CEO raising capital. View in LinkedIn